Keyphrases
Acute Myeloid Leukemia
12%
Adult Patients
11%
Adverse Events
19%
All-cause Mortality
21%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
18%
Anemia
15%
Antibiotics
10%
Bacterial Infection
11%
Bendamustine
9%
Cancer Patients
16%
Chemotherapy
19%
Chronic Myeloid Leukemia
10%
Community-acquired Pneumonia
8%
Confidence Interval
60%
Diffuse Large B-cell Lymphoma (DLBCL)
8%
Fever of Unknown Origin
9%
Follicular Lymphoma
12%
Hazard Ratio
17%
Hematological Malignancies
12%
Hemoglobin
10%
Hemoglobin Level
7%
Hospitalization
10%
Infection Rate
10%
Infectious Complications
8%
Intravenous Iron
12%
Israel
7%
Maintenance Therapy
9%
Meta-analysis
100%
Meta-analysis of Randomized Controlled Trials
22%
Neutropenia
7%
Neutropenic Patients
8%
Odds Ratio
8%
Oncology Patients
11%
Overall Survival
19%
Patients with Hematological Malignancies
8%
Placebo
10%
Positron Emission Tomography-computed Tomography (PET-CT)
16%
Progression-free Survival
7%
Randomized Controlled Trial
23%
Randomized Trial
10%
Relative Risk
39%
Retrospective Cohort Study
24%
Risk Factors
7%
Risk Ratio
20%
Rituximab
11%
Sepsis
8%
Systematic Meta-analysis
97%
Thrombocytopenia
9%
Tyrosine Kinase Inhibitor
9%
Venous Thromboembolism
13%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
10%
Adverse Event
21%
All Cause Mortality
21%
Anemia
18%
Antibiotic Prophylaxis
6%
Antibiotics
9%
Aplastic Anemia
6%
Azacitidine
5%
Bacterial Infection
11%
Bendamustine
9%
Bleeding
7%
Bloodstream Infection
8%
Ceftriaxone
7%
Chemotherapy
23%
Chronic Kidney Failure
6%
Chronic Lymphatic Leukemia
7%
Chronic Myeloid Leukemia
5%
Ciclosporin
6%
Cohort Study
28%
Community Acquired Pneumonia
8%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
5%
Diffuse Large B Cell Lymphoma
7%
Diseases
21%
Follicular Lymphoma
10%
Hematologic Malignancy
17%
Immunosuppressive Agent
5%
Inappropriate Vasopressin Secretion
6%
Infection
53%
Infection Rate
5%
Infectious Complication
6%
Iron
18%
Malignant Neoplasm
23%
Meningococcosis
6%
Monotherapy
5%
Mortality Rate
5%
Myelodysplastic Syndrome
7%
Neutropenia
9%
Overall Survival
19%
Placebo
11%
Polyethylene Terephthalate
5%
Protein Tyrosine Kinase Inhibitor
6%
Quinolone Derivative
5%
Randomized Controlled Trial
41%
Remission
9%
Retrospective Study
8%
Rifampicin
6%
Rituximab
17%
Sepsis
8%
Thrombocytopenia
9%
Venous Thromboembolism
20%
Medicine and Dentistry
Acute Myeloid Leukemia
5%
Adverse Event
10%
All Cause Mortality
11%
Anemia
21%
Antibiotics
5%
Anticoagulation
5%
Arm
7%
B-Cell Chronic Lymphocytic Leukemia
5%
Bendamustine
5%
Bloodstream Infection
7%
Cancer
14%
Cell Transplantation
7%
Chronic Kidney Disease
5%
Cohort Analysis
7%
Diffuse Large B-Cell Lymphoma
8%
Diseases
13%
Febrile Neutropenia
5%
Fever of Unknown Origin
8%
Fluorodeoxyglucose F 18
6%
Follicular Lymphoma
6%
Graft Failure
5%
Hazard Ratio
9%
Hematologic Malignancy
13%
Hematopoietic Cell
8%
Immunosuppressive Treatment
5%
Infection
34%
Infectious Complication
5%
Iron
16%
Iron Deficiency
7%
Kidney Graft
8%
Kidney Transplantation
5%
Maintenance Therapy
6%
Malignant Neoplasm
17%
Meta-Analysis
67%
Neutropenia
6%
Odds Ratio
7%
Overall Survival
14%
Platelet
5%
Polyethylene Terephthalate
7%
Positron Emission Tomography-Computed Tomography
16%
Progression Free Survival
5%
Randomized Controlled Trial
22%
Retrospective Cohort Study
19%
Retrospective Study
8%
Rituximab
10%
Sepsis
6%
Supplementation
8%
Systematic Review
58%
Thrombocytopenia
7%
Venous Thromboembolism
11%